ACRS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ACRS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Aclaris Therapeutics's annualized return on invested capital (ROIC %) for the quarter that ended in Sep. 2024 was -72.09%.
As of today (2024-12-15), Aclaris Therapeutics's WACC % is 8.27%. Aclaris Therapeutics's ROIC % is -94.69% (calculated using TTM income statement data). Aclaris Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.
The historical data trend for Aclaris Therapeutics's ROIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aclaris Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
ROIC % | Get a 7-Day Free Trial | -139.97 | -221.86 | -175.67 | -201.10 | -217.92 |
Aclaris Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
ROIC % | Get a 7-Day Free Trial | -111.61 | -106.69 | -109.17 | -110.82 | -72.09 |
For the Diagnostics & Research subindustry, Aclaris Therapeutics's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Aclaris Therapeutics's ROIC % distribution charts can be found below:
* The bar in red indicates where Aclaris Therapeutics's ROIC % falls into.
Aclaris Therapeutics's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:
ROIC % (A: Dec. 2023 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (A: Dec. 2022 ) | + | Invested Capital (A: Dec. 2023 )) | / count ) |
= | -116.314 * ( 1 - 0.41% ) | / | ( (31.227 | + | 75.087) | / 2 ) |
= | -115.8371126 | / | 53.157 | |||
= | -217.92 % |
where
Invested Capital | (A: Dec. 2022 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 254.596 | - | 13.757 | - | ( 217.571 | - | max(0, 21.938 | - | 231.55 | + | 217.571 | )) |
= | 31.227 |
Invested Capital | (A: Dec. 2023 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 197.405 | - | 24.414 | - | ( 119.106 | - | max(0, 30.952 | - | 128.856 | + | 119.106 | )) |
= | 75.087 |
Aclaris Therapeutics's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Sep. 2024 is calculated as:
ROIC % (Q: Sep. 2024 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (Q: Jun. 2024 ) | + | Invested Capital (Q: Sep. 2024 )) | / count ) |
= | -38.684 * ( 1 - 0% ) | / | ( (48.225 | + | 59.099) | / 2 ) |
= | -38.684 | / | 53.662 | |||
= | -72.09 % |
where
Invested Capital | (Q: Jun. 2024 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 161.071 | - | 10.893 | - | ( 111.093 | - | max(0, 15.682 | - | 117.635 | + | 111.093 | )) |
= | 48.225 |
Invested Capital | (Q: Sep. 2024 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 182.394 | - | 9.781 | - | ( 127.722 | - | max(0, 18.816 | - | 132.33 | + | 127.722 | )) |
= | 59.099 |
Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aclaris Therapeutics (NAS:ACRS) ROIC % Explanation
ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROIC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Aclaris Therapeutics's WACC % is 8.27%. Aclaris Therapeutics's ROIC % is -94.69% (calculated using TTM income statement data).
Be Aware
Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Thank you for viewing the detailed overview of Aclaris Therapeutics's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Anand Mehra | director | 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
Joseph Monahan | officer: Chief Scientific Officer | C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087 |
Kevin Balthaser | officer: Chief Financial Officer | C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087 |
James Loerop | officer: Chief Business Officer | C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087 |
Douglas J. Manion | officer: Pres and COO | C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087 |
Neal Walker | director, officer: President and CEO | 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803 |
Andrew N Schiff | director | PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022 |
Gail Cawkwell | officer: Chief Medical Officer | C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087 |
Frank Ruffo | officer: Chief Financial Officer | C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355 |
David N. Gordon | officer: Chief Medical Officer | C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355 |
Kamil Ali-jackson | officer: Chief Legal Officer | C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355 |
James B. Tananbaum | 10 percent owner | 3052 PACIFIC AVENUE, SAN FRANCISCO CA 94115 |
Foresite Capital Management Iii, Llc | 10 percent owner | 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939 |
Foresite Capital Fund Iii, L.p. | 10 percent owner | 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111 |
Foresite Capital Fund Iv, L.p. | 10 percent owner | 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111 |
From GuruFocus
By GuruFocus Research • 02-06-2024
By GuruFocus News • 11-23-2024
By Marketwired • 11-26-2024
By Marketwired • 05-07-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By Marketwired • 07-16-2024
By GuruFocus News • 11-19-2024
By Marketwired • 08-07-2024
By PRNewswire • 04-23-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.